Dissolution Testing For Inhaled drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Dissolution Testing For Inhaled drugs
Although there are no regulatory requirements or established pharmacopoeial techniques for the dissolution testing of inhaled drugs, such testing can potentially open up the opportunity to tailor formulation properties. The authors explain how a new technique using standard dissolution test equipment in combination with US Pharmacopeia methods for the dissolution testing of solid dosage forms can be used to differentiate the solubility of orally inhaled products.


Pharmaceutical Technology Europe
Volume 22, Issue 11

Optimising a dissolution test method for inhalation formulations

Through a series of experiments, factors associated with each step of the test process — from dose collection through to solution sampling method — were investigated to develop an optimal test procedure for use with this new apparatus.10 The following discussion tracks the experiment path taken and its outcome.

Tests to establish optimal conditions were carried out using budesonide (BD) and albuterol sulphate (AS), which are routinely used to treat asthma. BD and AS were fired into the NGI with a Pulmicort Flexhale DPI (AstraZeneca) and Ventolin HFA MDI (GlaxoSmithKline), respectively. Multiple actuations ensured the presence of sufficient sample on the collection surface in initial tests; however, the actuation number was one of the variables investigated as part of the experimental programme.

The test flow rate through the NGI was set at 30 L/min for the Ventolin HFA and 60 L/min for the Pulmicort Flexhaler. These air flow rates were established with reference to pharmacopeial monographs for the testing of MDIs and DPIs.11,12 The monographs stipulate that the flow rate should be set to 30 L/min when testing an MDI (using the NGI) and at a flow rate to give a pressure drop across the device of 4 kPa when testing a DPI. Calibration data for the NGI allows the accurate determination of stage cutoff diameters at both of these flow rates.13

Following size fractionation of the sample in the NGI, the removable impaction surface from the dissolution cup was covered with a polycarbonate membrane (pre-soaked in dissolution fluid) and secured in the membrane holder. This entire assembly was then placed at the bottom of a vessel of a standard USP Method 2 apparatus containing 300 mL of dissolution fluid.

During dissolution testing, 3 mL samples were periodically withdrawn from the vessel for analysis using a validated HPLC method. A corresponding volume of fresh dissolution medium was added after each extraction. With the BD, sample testing took place over a period of 2 h, while 1 h proved sufficient for AS. At the end of the experiment, the residual material on the membrane was recovered and quantified.

Selecting an optimal collection surface for dose collection

Using the dissolution cup it is possible to select one fraction with which to compare one drug to another, or to assess the influence of particle size on dissolution rate by testing different fractions of the dose. With the Pulmicort Flexhaler (BD) stage 4 consistently displayed the maximum deposition while for the Ventolin HFA (AS) it was stage 5. These stages were therefore selected for dose collection for subsequent tests. Stage 4 has a cutoff diameter of 1.66 m at 60 L/min, while stage 5 has a cut-off diameter of 1.36 m at an air flow rate of 30 L/min.


Figure 3: Exploring the influence of particle size on dissolution profile for budesonide.
For the BD, dissolution profiles were determined as a function of particle size by collecting samples on stage 2 through 5 (Figure 3). Eighty percent of the samples collected on stages 2, 3 and 4 dissolved after 15 min, but there were differences in initial dissolution rates. Statistical analysis shows similarity factors* of 52.5 and 59.7 for stages 2 and 3 compared with stage 4 (the reference stage), but the dissolution profile for stage 5 is significantly different (a similarity factor of 40.6). The smaller particles on this stage, which has a cut-off diameter of 0.94 m, have a large surface area to volume ratio and, therefore, might be expected to exhibit a faster dissolution rate in accordance with the standard NoyesWhitney model.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
25%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here